Pediatrix Medical Group, Inc.

Valuation Analysis

About the Company

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric inte

Pediatrix Medical Group, Inc. Stock at a Glance

Pediatrix Medical Group, Inc. (MD) is currently trading at $24.30 with a market capitalization of $2B. The trailing P/E ratio stands at 11.8x, with a forward P/E of 10.3x. The 52-week range spans from $11.84 to $24.99; the current price is 2.8% below the yearly high. Year-over-year revenue growth stands at +3.9%. The net profit margin stands at 9.02%.

💰 Dividend

Pediatrix Medical Group, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Pediatrix Medical Group, Inc. (MD) on consensus: None. The average price target is $23.17, implying -4.66% from the current price. Analyst price targets range from $19.00 to $27.00.

Pediatrix Medical Group, Inc.: The Investment Case in Detail

Pediatrix Medical Group, Inc. (MD) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 50% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue growth has slowed to just 3.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valuation in Context

With a PEG ratio of 0.24, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 8.6x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 10.3x is meaningfully below the trailing 11.8x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 94.8% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (5.81%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Pediatrix Medical Group, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.